Panacea Index Logo

Command Palette

Search for a command to run...

Antioxidant Nanoplatforms for Dermal Delivery: Melatonin.

Current drug metabolism
January 1, 2017
Aroha Sanchez Milan et al. (3 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to review nanocarrier strategies for dermal melatonin delivery and assess its potential biomedical and cosmetic applications.

Results Summary

The review found that nanoplatforms like liposomes and polymeric nanoparticles enhance melatonin's dermal delivery by preventing premature oxidation and improving skin permeation, with promising in vitro and in vivo results.

Population

Not specified (review of existing literature).

Effective Dosage

Not specified.

Duration

Not specified.

Interactions

None mentioned.

Extracted Claims (5)
InterventionDirectionEndpointPopulationDosageImpactClaim #
melatonin
decrease
cancer, inflammation and neurodegenerative diseases
-
-
is potentially effective
#1
nanoplatforms for the dermal melatonin delivery
increase
conventional melatonin administration
-
-
could improve the efficacy
#2
nanoplatforms for the dermal melatonin delivery
increase
drug stability
-
-
preservation of the drug from premature oxidation
#3
nanoplatforms for the dermal melatonin delivery
increase
drug permeation
-
-
enhancement of drug permeation through the skin
#4
nanoplatforms for the dermal melatonin delivery
increase
drug exposure time
-
-
providing greater exposure times
#5
Abstract

BACKGROUND: Melatonin is emerging as a promising therapeutic agent, mainly due to its role as antioxidant. Substantial evidences show that melatonin is potentially effective in a variety of diseases as cancer, inflammation and neurodegenerative diseases. The excellent antioxidant capacity with pharmacokinetics characteristics and the emerging search for new pharmaceutical nanotechnology based systems, make it particularly attractive to elaborate nanoplatforms based on melatonin for biomedical or cosmetic dermal applications. Different nanosystems for dermal delivery have been investigated. OBJECTIVE: This review focuses on nanocarrier production strategies, dermal melatonin application and delivery advances in vivo and in vitro. Equally, future perspectives of this assisted melatonin delivery have also been discussed. METHOD: In the current review, we have revised relevant articles of the available literature using the major scientific databases. RESULTS: One hundred and thirteen papers were included in the review, the majority of which represent latest researches in nanosized platforms for the dermal delivery of melatonin including liposomes, ethosomes, niosomes, polymeric nanoparticles, solid lipid nanoparticles and cyclodextrins. Furthermore, relevant papers reporting in vitro and in vivo application studies of these nano-based melatonin platforms were also discussed. CONCLUSION: The use of nanoplatforms for the dermal melatonin delivery as antioxidant agent could improve the efficacy of conventional melatonin administration due to the preservation of the drug from premature oxidation and the enhancement of drug permeation through the skin providing greater exposure times.

Medical Subject Headings (MeSH)
Administration, TopicalAntioxidantsHumansMelatoninNanostructuresSkin Absorption
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality78/10
Citation Metrics
Total Citations10
Citations/Year1.3
Relative Citation Ratio0.57
NIH Percentile30.7%
Research Impact Scores
APT Score0.25
Weight Score1.86
Normalized Score0.70
Related Supplements